Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
News
ABIM unlinks MOC enrollment from board certification
Publish date:
August 4, 2015
References
agallegos@frontlinemedcom.com
On Twitter
@legal_med
Pages
« first
1
2
Recommended Reading
AMA Town Hall: Doctors call for meaningful use delay
MDedge Hematology and Oncology
Good news, bad news in the Medicare trustees report
MDedge Hematology and Oncology
Study questions whether MOC is worth the time
MDedge Hematology and Oncology
Value-based care poses new legal risks for doctors
MDedge Hematology and Oncology
Drug manufacturers delayed reporting serious unexpected adverse events
MDedge Hematology and Oncology
Medicare hospital-related mortality down since 1999
MDedge Hematology and Oncology
Update on informed consent
MDedge Hematology and Oncology
Coding mistakes lead to $35 million in drug overpayments
MDedge Hematology and Oncology
PCPC: Avoid these traps when prescribing medical marijuana
MDedge Hematology and Oncology
Whispered pectoriloquy
MDedge Hematology and Oncology
Practice Management
Business of Medicine
All Specialties
